[{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Glysious","sponsor":"Tetra Pharm Technologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Glysious","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glysious \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Glysious \/ Tetra Pharm Technologies"},{"orgOrder":0,"company":"Neumirna Therapeutics","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Series A Financing","leadProduct":"NMT.001","moa":"miR-134","graph1":"Neurology","graph2":"Preclinical","graph3":"Neumirna Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Neumirna Therapeutics \/ Angelini Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Neumirna Therapeutics \/ Angelini Ventures"},{"orgOrder":0,"company":"Hoba Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"Recombinant Human Meteorin","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoba Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoba Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Hoba Therapeutics \/ Indaco Venture Partners"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Vesper Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Preclinical","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Orphazyme \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The proceeds from the financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy.

                          Product Name : NMT.001

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 08, 2025

                          Lead Product(s) : NMT.001

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Angelini Ventures

                          Deal Size : $20.9 million

                          Deal Type : Series A Financing

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : IRX4204 is the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS).

                          Product Name : IRX4204

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 16, 2024

                          Lead Product(s) : IRX4204

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.

                          Product Name : TPT0201

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 24, 2024

                          Lead Product(s) : TPT0201

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Tetra Pharm Technologies

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funding aims to support the clinical advancement of Vesper's lead product VES001, a sortilin inhibitor. Currently, it is being evaluated in the preclinical trial studies for Parkinson's disease.

                          Product Name : VES001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : VES001

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                          Deal Size : $0.8 million

                          Deal Type : Funding

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The net proceeds will be used to advance new drug candidate, HB-086, a non-opioid compound with a unique mode of action, targeting the underlying cause in the peripheral nervous system against chronic neuropathic pain.

                          Product Name : HB-086

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          November 12, 2023

                          Lead Product(s) : Recombinant Human Meteorin

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Indaco Venture Partners

                          Deal Size : $25.0 million

                          Deal Type : Series A Financing

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Novo Nordisk announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.

                          Product Name : Rybelsus

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 16, 2020

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).

                          Product Name : Miplyffa

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 17, 2020

                          Lead Product(s) : Arimoclomol Citrate

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank